ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit .PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC.
新澤西州普林斯頓，2024年11月26日（環球新聞）-- ANI製藥公司（"ANI"或"公司"）（納斯達克：ANIP）今天宣佈，總裁兼首席執行官Nikhil Lalwani和首席財務官Stephen Carey將於2024年12月4日下午3點在紐約市舉辦第36屆派傑投資醫療大會的爐邊聊天。
The live and archived webcast will be accessible from the Company's website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.
公司的直播和錄製的網絡廣播將可以從公司網站訪問， 在投資者部分的活動和演示下。網絡廣播的重播將在90天內可用。
About ANI Pharmaceuticals, Inc.
關於ANI Pharmaceuticals，Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit .
ANI製藥公司（納斯達克：ANIP）是一家多元化的生物製藥公司，致力於其「服務患者，改善生活」的使命，通過開發、製造和商業化創新和高質量的治療藥物來實現。該公司專注於通過其罕見疾病業務提供可持續增長，該業務在眼科醫療、風溼科、腎病科、神經科和肺科等領域營銷新產品；其仿製藥業務利用研發專長、運營卓越和美國本土製造；以及其成熟品牌業務。有關更多信息，請訪問 .
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
投資者關係：
英未泰客，內部溝通公司
電話：212-452-2793
E: lwilson@insitecony.com
Source: ANI Pharmaceuticals, Inc.
來源：ANI Pharmaceuticals, Inc.
譯文內容由第三人軟體翻譯。